Previous 10 | Next 10 |
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer’s disease (AD) cohort in ABATE Phase 1b/2 trial; Further ABATE immunogenicity and safety...
2023-04-13 07:24:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time for another dive into the biggest pre-market stock movers as we see what’s moving the market on Thursday morning! Penny stocks are on the rise today and weȁ...
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease Webinar to take place on Tuesday, April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST Lausanne, Switzerland, April 5 , 202 3 – AC Immune...
2023-04-03 08:55:13 ET Summary In December of 2022 I introduced a number of stocks which I was adding to my "Tax Loss Selling Basket". In this article I summarize the logic and criteria for the basket. I then tally up the results including calculating overall returns and looki...
AC Immune at AD/PD ™ 202 3 to Present New Clinical and Preclinical Data f rom its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD TM ) AC Immune ...
2023-03-18 09:00:00 ET Summary ACIU is a leading researcher in the field of dementia, with major deals with big pharma. Unfortunately, AD is a tough space and none of its molecules have turned out well so far. That could change, and the stock could rise, but it is just too ris...
2023-03-16 07:57:43 ET AC Immune press release ( NASDAQ: ACIU ): FY Non-GAAP EPS of -CHF 0.81. Revenue of CHF 3.9M. For further details see: AC Immune Non-GAAP EPS of -CHF 0.81, revenue of CHF 3.9M
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023 ACI-24.060 anti-amyloid-be...
2023-03-15 11:30:26 ET Major earning expected before the bell on Thursday include: Cresco Labs ( OTCQX:CRLBF ) Dollar General ( DG ) Jabil ( JBL ) Hello Group ( MOMO ) Williams-Sonoma ( WSM ) For further details see: Notable earnings befor...
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland, March 8 , 202 3 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for n...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...